Elizabeth Warren (D-MA)
Pharmaceutical Investment Oversight and Accountability Act
A Democratic bill with 1 Republican cosponsor · See all 2 cosponsors
Last activity — Read twice and referred to the Committee on Banking, Housing, and Urban Affairs.
In committee
Introduced and handed to a committee in the chamber it started in.
The committee holds it, and most bills are never heard from again. A hearing or a committee vote would be news; silence is the usual outcome, and it kills the bill without anyone voting against it.
Its path through Congress
- Introduced
- In Committee
What this bill would do
This bill, called the "Pharmaceutical Investment Oversight and Accountability Act," requires the Federal Trade Commission (FTC) to report on foreign investment in the U.S. pharmaceutical industry. The FTC must work with the Secretary of the Treasury and provide these reports annually to specific congressional committees and health officials. These reports will assess pharmaceutical supply chains and the domestic capacity to produce drugs. The reports will also look at foreign investment regarding the storage and sequencing of DNA. Additionally, the FTC must include data on reviews and investigations of covered transactions from the previous 10 fiscal years. A summary of the report must be made available to the public on the FTC website.
Yes· 3 of 9
- Scored +5
Does this make what the government does easier for the public to see?
Requires the FTC to publish an unclassified summary of foreign pharmaceutical investment for the public.
- Scored +4
Does this make the country readier for the next outbreak?
Analyzing pharmaceutical supply chain reliance on foreign manufacturing enhances readiness for health crises.
- Scored +3
Does this protect people from being watched or searched?
Increased oversight of DNA sequencing and storage by foreign entities supports the privacy of genomic data.
The opposite
- Scored -1
Does this make trade with other countries easier?
Increased scrutiny of foreign investment may create a more restrictive environment for international pharmaceutical trade.
Who it would affect, and how
Potential Positive Impacts for People
-
Increased Oversight of Drug Production: By assessing the effect of foreign investment on the domestic capacity to produce drugs and their ingredients, the bill provides data on U.S. manufacturing capabilities (Section 2(b)(1)(B)).
-
Supply Chain Analysis: The bill requires an assessment of the pharmaceutical supply chain and how relying on foreign manufacturing affects the industry (Section 2(b)(1)(A)).
-
DNA Technology Monitoring: The bill examines how foreign investment affects the U.S. capacity to store or sequence DNA, including genome and exome analysis (Section 2(b)(1)(C)).
-
Public Transparency: The requirement for the FTC to publish an unclassified summary of the report on a public website allows the people to access information regarding foreign pharmaceutical investment (Section 2(d)).
Potential Negative Impacts for People
- No negative impacts for individuals or groups of people are explicitly mentioned in the provided text.
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Tap or hover a score for the reason it gave.
- Governance And Ideology
- Does this make what the government does easier for the public to see? — Requires the FTC to publish an unclassified summary of foreign pharmaceutical investment for the public. Does this protect people from being watched or searched? — Increased oversight of DNA sequencing and storage by foreign entities supports the privacy of genomic data. Does this give the federal government more power? — The bill expands the reporting and oversight mandates of the FTC.
- Healthcare
- Does this make the country readier for the next outbreak? — Analyzing pharmaceutical supply chain reliance on foreign manufacturing enhances readiness for health crises. Does this make health care easier to get in general? — Reporting on domestic drug production capacity helps identify and address gaps in healthcare access.
- Demographic And Interest Groups
- Would retired people be better off under this? — Retirees benefit from the increased security and stability of the domestic pharmaceutical supply chain. Would people over 65 be better off under this? — Seniors are frequent users of pharmaceutical products and benefit from more secure drug supply chains.
- Education And Technology
- Does this give people more control over their personal data? — Monitoring foreign investment in DNA storage and sequencing helps protect sensitive genomic data.
- Economy And Finance
- Does this give people more protection from unfair business practices? — Increased oversight of pharmaceutical supply chains can lead to better drug availability and consumer security.
- National Security And Foreign Policy
- Does this make trade with other countries easier? — Increased scrutiny of foreign investment may create a more restrictive environment for international pharmaceutical trade.
- 7/15/2026
- Read twice and referred to the Committee on Banking, Housing, and Urban Affairs.
- 2 Cosponsors added.
- Introduced in Senate
One bill Congress.gov lists as related to this one — companions in the other chamber, earlier versions, and bills this one absorbed or was folded into.
Kirsten GillibrandDemocrat · New York
Rick ScottRepublican · Florida